NCT01386398 2015-01-21Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell LymphomaEuropean Organisation for Research and Treatment of Cancer - EORTCPhase 3 Withdrawn